Research progress of molecular imaging of nuclide-radiolabeled HER2 antibodies and nanobodies

SONG Hongjie; ZHOU Zhiguo; SONG Shaoli; WANG Mingwei

doi:10.19732/j.cnki.2096-6210.2020.05.015

您当前的位置：

首页 >

文章列表页 >

Research progress of molecular imaging of nuclide-radiolabeled HER2 antibodies and nanobodies

更新时间：2025-12-15

- Research progress of molecular imaging of nuclide-radiolabeled HER2 antibodies and nanobodies
- Vol. 29, Issue 5, Pages: 510-519(2020)
- 作者机构：
  
  上海师范大学化学与材料科学学院,上海,200234
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2020.05.015
  CLC：
- Published Online：28 October 2020，
  
  Published：28 October 2020
- 稿件说明：
移动端阅览
宋宏杰,周治国,宋少莉,等. 放射性核素标记HER2抗体和纳米抗体的分子影像研究进展[J]. 肿瘤影像学, 2020, 29(5): 510-519 https://doi.

org/10.19732/j.cnki.2096-6210.2020.05.015
宋宏杰,周治国,宋少莉,等. 放射性核素标记HER2抗体和纳米抗体的分子影像研究进展[J]. 肿瘤影像学, 2020, 29(5): 510-519 https://doi. DOI： 10.19732/j.cnki.2096-6210.2020.05.015.

org/10.19732/j.cnki.2096-6210.2020.05.015 DOI：

摘要

人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）在多种癌症（如乳腺癌、卵巢癌）中高表达，是一个重要的肿瘤分子靶点，临床上迫切需要发展体内检测肿瘤组织HER2表达水平的分子影像学方法。核素分子影像即正电子发射断层成像（positron emission tomography，PET）/电子计算机断层扫描（computed tomography，CT）和单光子发射计算机断层成像（single-photon emission computed tomography，SPECT）/CT具有全身、半定量、实时和动态等内在优势，已经成为肿瘤精准诊断和治疗的重要手段，因此，核素标记HER2靶向的分子影像探针及其应用研究获得了快速发展。本文重点综述了核素标记HER2完整抗体和纳米抗体的分子影像探针及HER2阳性肿瘤PET/CT和SPECT/CT显像的研究进展。

Abstract

Human epidermal growth factor receptor 2 (HER2)

as an important molecular target of tumor

is overexpressed in many kinds of cancers

such as breast cancer

ovarian cancer. It is urgent for the clinic to develop in vivo molecular imaging methods to detect HER2 expression in tumor tissues. Radionuclide-based molecular imaging

including positron emission tomography (PET)/computed tomography (CT) and single-photon emission computed tomography (SPECT)/CT

embracing whole body

semi- quantitative

real-time and dynamic inherent advantages

have become the key players in the precise diagnosis and treatment of tumors

therefore

radionuclide-labeled

HER2-targeted molecular image probes and the related applications have been developed extensively. In this paper

the research progress of molecular imaging probes based on radionuclide-labeled HER2 full-sized antibodies and nanobodies as well as their PET/CT and SPECT/CT imaging of HER2 positive tumors were concisely reviewed.

关键词

Keywords

references

Views

1069

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Computer-aided design of a novel HER2-targeted cyclic peptide PET probe and its evaluation for noninvasive imaging of breast cancer

Site-specific development and preclinical evaluation of ⁶⁸Ga-THP-ACN376, a CLDN18.2-targeted nanobody probe

FAPI in radionuclide theranostics: toward a new emerging paradigm for tumor management

Research progress in the application of T1 mapping technology in tumor lesions

The diagnostic value of quantitative and qualitative parameters of STE and SE in BI-RADS 4 breast lesions and their correlation with HER2 expression

Related Author

YAO Ying

GAO Xiaomin

GUO Xu

Hua ZHU

Zhi YANG

Yuwen YANG

Chang LIU

Hui YANG

Related Institution

Department of Pharmacy, Wuxi Maternal and Child Health Care Hospital

Wuxi Medical College, Jiangnan University

Department of Pharmacy, Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University

Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, National Medical Products Administration, Beijing Key Laboratory of Carcinogenesis and Translational Research

Institute of Medical Technology, Peking University Health Science Center

AI问答

⁰